Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
